A biologically active composition comprising: (a) at least one of the following biologically active components: (i) a nucleic acid; (ii) a nucleoside, nucleotide; (iii) a peptide, protein; (iv) a lipopolysaccharide; (v) a peptidoglycan; (vi) a carbohydrate; (vii) a lipid; (viii) a lipopeptide; (ix) a thiol that is selected from the group consisting of glutathione and N-acetylcysteine; (x) an antibiotic; (xi) a vitamin; (xii) a bioflavonoid; (xiii) an antioxidant that is selected from the group consisting of glutathione, vitamin A, vitamin C, vitamin E, curcumin, uric acid, lipoic acid, a carotene, and ubiquinol; (xiv) an immune response modifier that is imiquimod; (xv) an antibody; (vxi) histamine or an antihistamine; and (xvii) a kinase inhibitor that is selected from the group consisting of BIBW 2992, imatinib, gefinitib, pegaptanib, sorafenib, dasatinib, sunitinib, nilotinib, lapatinib, rapamycin, and FK506; and (b) at least one biopolymer microparticle carrier effective to deliver the composition to a phagocytic cell such that the biologically active component is taken up by the phagocytic cell and influences its biological activity, wherein the at least one biologically active component is reversibly linked to the microparticles through a linkage selected from the group consisting of disulfide linkages and linkages comprising immobilized metal chelates, and wherein the biopolymer microparticle carrier is agarose microparticles in the 1-10 μm range. (a) at least one of the following biologically active components: (i) a nucleic acid; (ii) a nucleoside, nucleotide; (iii) a peptide, protein; (iv) a lipopolysaccharide; (v) a peptidoglycan; (vi) a carbohydrate; (vii) a lipid; (viii) a lipopeptide; (ix) a thiol that is selected from the group consisting of glutathione and N-acetylcysteine; (x) an antibiotic; (xi) a vitamin; (xii) a bioflavonoid; (xiii) an antioxidant that is selected from the group consisting of glutathione, vitamin A, vitamin C, vitamin E, curcumin, uric acid, lipoic acid, a carotene, and ubiquinol; (xiv) an immune response modifier that is imiquimod; (xv) an antibody; (vxi) histamine or an antihistamine; and (xvii) a kinase inhibitor that is selected from the group consisting of BIBW 2992, imatinib, gefinitib, pegaptanib, sorafenib, dasatinib, sunitinib, nilotinib, lapatinib, rapamycin, and FK506; and (i) a nucleic acid; (ii) a nucleoside, nucleotide; (iii) a peptide, protein; (iv) a lipopolysaccharide; (v) a peptidoglycan; (vi) a carbohydrate; (vii) a lipid; (viii) a lipopeptide; (ix) a thiol that is selected from the group consisting of glutathione and N-acetylcysteine; (x) an antibiotic; (xi) a vitamin; (xii) a bioflavonoid; (xiii) an antioxidant that is selected from the group consisting of glutathione, vitamin A, vitamin C, vitamin E, curcumin, uric acid, lipoic acid, a carotene, and ubiquinol; (xiv) an immune response modifier that is imiquimod; (xv) an antibody; (vxi) histamine or an antihistamine; and (xvii) a kinase inhibitor that is selected from the group consisting of BIBW 2992, imatinib, gefinitib, pegaptanib, sorafenib, dasatinib, sunitinib, nilotinib, lapatinib, rapamycin, and FK506; and (b) at least one biopolymer microparticle carrier effective to deliver the composition to a phagocytic cell such that the biologically active component is taken up by the phagocytic cell and influences its biological activity, wherein the at least one biologically active component is reversibly linked to the microparticles through a linkage selected from the group consisting of disulfide linkages and linkages comprising immobilized metal chelates, and wherein the biopolymer microparticle carrier is agarose microparticles in the 1-10 μm range.